29/100Is RKLB-Rocket Lab USA, a buy?
Tuesday 11 August 2026
Why now: The stock is being repriced lower after very recent company updates and an earnings window, while the business continues to add meaningful government and future-Neutron backlog signals. This is a “fundamentals and program execution” story right now, not a momentum setup, so timing is about whether you believe Neutron and defense programs will convert into improving cash flow over the next 12–24 months.
Upside: Street targets imply about 43% upside versus the latest price snapshot in the fact pack, but that upside depends on hitting major milestones (especially Neutron schedule and margin improvement). A re-rating higher is plausible if cash burn narrows materially while backlog converts into revenue at higher gross margin.
Risks: Neutron schedule slips or early reliability issues could damage customer trust and delay the business model shift the valuation assumes. The other core risk is sustained negative free cash flow that forces more dilution even if revenue grows.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free — no credit card needed.
Scorecard
| Scorecard | 29/100 | |
|---|---|---|
| Company Detail | RKLB - Rocket Lab USA, Inc. | |
| Price as at 11 August 2026 | $77.12 | |
| Market cap | $45.1B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 2/20 | |
| Rev/EPS Momentum /20 | 0/20 | |
| Business Quality /15 | 8/15 | |
| Balance Sheet /15 | 3/15 | |
| Valuation /10 | 2/10 | |
| Industry Relative Strength /10 | 4/10 | |
| Macro / Sector Tailwind /10 | 10/10 | |
| Growth | ||
| Cash runway | 6.6 yr | |
| Revenue YoY | +38.0% | |
| EPS YoY | +2.6% | |
| FCF YoY | -177.5% | |
| Gross margin | 34.4% | |
| Valuation & Trend | ||
| Trailing P/E | neg | |
| Forward P/E | — | |
| RSI (14d) | 50 | |
| vs 50d SMA | -12.2% | |
| Support cushion | −4.1% | |
| Sentiment | ||
| Wall Street verdict | Mixed | |
| News tone | Positive | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Tuesday 11 August 2026
Sir Peter Beck has been Founder, Chairman, President and Chief Executive Officer since Rocket Lab became public in 2021 and previously led the company as its founder.
Adam Spice serves as Chief Financial Officer and Treasurer and has held the CFO role through Rocket Lab’s public-company period.
Receiver of capital expenditure: Yes — Rocket Lab is a receiver of customer capital expenditure because its customers fund launches, spacecraft, and multi-year defense and science programs that require ongoing hardware build and mission operations spend.
Main customers
- United States Space Force (Government customer for space-based sensing and responsive space capabilities; recent awards support spacecraft build, launch, and operations.)
- NASA (Science and exploration customer selecting Rocket Lab for launch services and mission support.)
- Commercial constellation operators (Commercial satellite companies buying Electron launches today and reserving future Neutron capacity for dedicated constellation deployment.)
Notable contracts
- SB-AMTI program contract (Space Force) — $397 million (announced August 4, 2026) (Rocket Lab to develop, launch, and operate multiple Flatellite spacecraft with an option for additional satellites included in the total value; launches planned on Neutron with mission operations provided by Rocket Lab.)
- Kepler Communications Neutron dedicated mission (Dedicated Neutron mission from Wallops Island, Virginia, no earlier than 2028, to deploy multiple satellites to low Earth orbit as Kepler expands its constellation.)
- Rocket Lab is building a rare end-to-end space company: small launch plus spacecraft manufacturing plus mission operations, with an explicit push into defense programs that can be larger and stickier than pure commercial launch.
- The long-term value hinges on Neutron moving from a development promise to a repeatable service and on space systems scaling with improving unit economics.
- The near-term setup is weak, but the strategic direction is supported by real customer wins and a strong macro demand backdrop in defense and resilient space architectures.
Show 5 headlines from the last 7d
Scores 29 out of 100 — a mixed overall grade. Sector fit scored highest. Business quality was fair but not a standout driver. Relative strength versus its industry and balance sheet weighed on the total. The score is capped by two issues that matter for a 1+ year hold: valuation is extremely high relative to current revenue (EV/Sales about 56x) while free cash flow is deeply negative, and the current technical setup is weak (well below the 50-day average with no breakout confirmation). Mechanical cap: latest annual net income ≤ 0 — Balance Sheet ≤ 3/15, Rev/EPS ≤ 0/20, overall ≤ 50/100.
Component scores are on the scorecard above.
- At the latest print ($77.95), the stock is below its 50-day moving average by roughly 12% and slightly below its 200-day by about 1%, with no breakout state and no recent 50-day reclaim signal.
- Volume expansion is not present (vol× well under 1.0), and industry relative strength is slightly below neutral, which fits the idea that this is currently a de-risking phase rather than a fresh leadership move.
- The company is still loss-making on a trailing basis (net income about -$198 million) and free cash flow is deeply negative (about -$322 million), which is the main fundamental red flag given the very large market value.
- Gross margin is solid for this stage (34.4% latest), and liquidity is strong with about $2.13 billion of cash and a high current ratio (about 5.48), which reduces near-term financing risk.
- Dilution remains a real cost to shareholders (share count up about 18.5% over 5 years).
- Profitability metrics are negative (ROE, ROIC, ROA all below zero), so the investment case still depends on future scale and operational leverage rather than proven earnings power today.
Cash runway: 6.6 yr ($2.1B cash ÷ $322M/yr burn, latest fiscal year).
Upcoming (1–6 months)
- Next 1–2 quarters: management updates on Neutron development milestones, launch-readiness timing, and any firm schedule commitments tied to customer missions.
Ongoing
- Cash burn and dilution: quarterly free cash flow trend, share count changes, and whether gross margin can hold or improve as program mix shifts.
Risks
- Neutron delays, cost overruns, or early performance issues could push out revenue, weaken customer confidence, and force additional financing at unfavorable terms.
- Valuation risk is high: even solid execution can be “not enough” if growth or margin expansion comes in slower than the market already expects.
Breaks the thesis
- Fundamental invalidation: free cash flow remains deeply negative while share dilution accelerates, indicating the model is not moving toward self-funding scale.
- Technical invalidation for momentum-style ownership: continued inability to reclaim the 50-day moving average with persistently weak volume, signaling the market is not ready to re-rate the story.
